NEW YORK, Jan. 11, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of New Oriental Education & Technology Group Inc. American Depositary Shares (NYSE:EDU) from September 27, 2016 through December 1, 2016, both dates inclusive (the “Class Period”) of the important February 13, 2017 lead plaintiff deadline. The lawsuit seeks to recover damages for New Oriental investors under the federal securities laws.
To join the New Oriental class action, go to http://www.rosenlegal.com/cases-1007.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) New Oriental engaged in college application fraud; and (2) as a result, Defendants’ statements about New Oriental’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. On December 2, 2016, Reuters reported that eight former and current New Oriental employees informed Reuters that New Oriental “engaged in college application fraud, including writing application essays and teacher recommendations, and falsifying high school transcripts.” On this news, shares of New Oriental fell $6.99 per share or over 14% from its previous closing price to close at $42.00 per share on December 2, 2016, damaging investors.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 13, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1007.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Instagram Outage Disrupts Thousands of U.S. Users
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Washington Post Publisher Will Lewis Steps Down After Layoffs
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 



